January 22, 2015
Drug repurposing is recognized to speed up patient access to new treatments. New tools are designed to discover new targets for medications that already have marketing authorization. One method described in the Orphanet Journal of Rare Diseases, “Homopharma”, is based on identifying potential new targets for existing compounds. The authors demonstrated that four flavonoid derivatives, used as anticancer compounds, were able to inhibit multiple protein-kinases with similar physiochemical properties. The authors believe that “the Homopharma concept can have the potential for understanding molecular binding mechanisms and providing new clues for drug development”.